Cortometrajes de vídeo

Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.

Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.

Patients with Multiple Myeloma and plasma cell disorders are at high risk of infections because of compromised immune system. Associated co morbidities can also increase susceptibility to certain infections.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.

Average at diagnosis of prostate cancer is ~65 years & patients usually have multiple co- morbidities and may be on treatment with multiple prescribed medications.

Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.

Metastatic Triple Negative Breast Cancer is still an unmet medical need.

Newer treatments like immunotherapy are associated with myocarditis which has high fatality rates & cardiovascular issues arising of CART cell therapy are often attributed to Cytokine Release Syndrome (CRS).

Wherever possible all patients with prostate cancer should undergo both germinal and somatic BRCA mutation testing as they represent predictive biomarkers of greater sensitivity to treatment with PARP inhibitors.